Merge Medical Startup Podcast

Merge Medical Startup Podcast

di Dr. Jeff Cole and Dr. Jeff Brown

Investimenti Medicina

Stagione 1

RHINOGRAM: Deep Dive Podcast

With an open rate of 99%, there simply isn’t a better form of Healthcare communication than texting. This multi-patented secure and HIPAA-compliant solution services 13 million patients with AI-driven team-based workflows and EMR/EHR integration. “Deep Dive” or uncut version of our video podcast. Drs Jeff Brown and Jeff Cole interview the founder of Rhinogram. Rhinogram’s complete digital communications and virtual care solution empowers healthcare facilities and their patients with the ability to initiate direct SMS/MMS HIPAA-compliant & secure text message communications across the full patient journey. Rhinogram was founded in 2015 by practicing orthodontist, Dr. Keith Dressler, with a vision to revolutionize how patients access care. Rhinogram serves over 13M patients in over 50+ healthcare specialties. Their mission is to provide equal access to care through simple, direct and reliable market leading patented technology. ***** Would this bring value to your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion. Sign up today! https://mergemedical.community.forum/ ***** DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

RHINOGRAM: 10 in 10 Podcast

With an open rate of 99%, there simply isn’t a better form of Healthcare communication than texting. This multi-patented secure and HIPAA-compliant solution services 13 million patients with AI-driven team-based workflows and EMR/EHR integration. “10 in 10” or quick hitting version of our video podcast. Drs Jeff Brown and Jeff Cole interview the founder of Rhinogram. Rhinogram’s complete digital communications and virtual care solution empowers healthcare facilities and their patients with the ability to initiate direct SMS/MMS HIPAA-compliant & secure text message communications across the full patient journey. Rhinogram was founded in 2015 by practicing orthodontist, Dr. Keith Dressler, with a vision to revolutionize how patients access care. Rhinogram serves over 13M patients in over 50+ healthcare specialties. Their mission is to provide equal access to care through simple, direct and reliable market leading patented technology. ***** Would this bring value to your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion. Sign up today! https://mergemedical.community.forum/ ***** DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

ENTAC MEDICAL: Deep Dive Podcast

Can acoustic biomarkers and AI be used to identify entry into disease state transition zones early enough to allow proactive decision making? Predict an ileus multiple days before it happens? Applications for cardiac and pulmonary disorders? “Deep Dive” or uncut version of our video podcast. Drs Jeff Brown and Jeff Cole interview the founders of Entac Medical. Entac Medical is a digital health company developing wearable devices. Their technology applies predictive analytics/AI to biological acoustic signals to predict downstream patient adverse events, improving patient outcomes, preventing hospital readmissions and reducing the cost of care. More specifically, they are using acoustic biomarkers to identify entry into disease state transition zones early enough to allow proactive decision making. In the treatment of post-operative ileus, this technology can significantly impact morbidity and mortality while also saving hospitals millions. Through an AI development platform, similar impact in cardiac and pulmonary disease states is hopeful. ***** Would this bring value to your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion. Sign up today! https://mergemedical.community.forum/ ***** DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

INTUSCOPE: Deep Dive Podcast

Can this patented Class I FDA Device featuring a reusable blade and reusable handle make intubation easier, faster, and safer in even the most difficult patients and most challenging environments? “Deep Dive” or uncut version of our video podcast. Drs Jeff Brown and Jeff Cole interview the founders of IntuScope, Charla and Keith Bartozzi. IntuScope was founded to pursue and commercialize a new approach to advance field and clinical intubation techniques, reduce the skill disparity, and improve patient outcomes. IntuScope is a patented Class I FDA Device featuring a reusable blade and reusable handle that utilizes a patient’s own anatomy and two actuating arms to open the airway. IntuScope makes intubation easier, faster, and safer in even the most difficult patients. While the device can be used for any intubation, the initial efforts will be focused on the pre-hospital market. ***** Would this bring value to your practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion. Sign up today! https://mergemedical.community.forum/ ***** DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

INTUSCOPE: 10 in 10 Podcast

Can this patented Class I FDA Device featuring a reusable blade and reusable handle make intubation easier, faster, and safer in even the most difficult patients and most challenging environments? “10 in 10” or quick-hitting version of our video podcast. Drs Jeff Brown and Jeff Cole interview the founders of Intuscope, Charla and Keith Bartozzi.. IntuScope was founded to pursue and commercialize a new approach to advance field and clinical intubation techniques, reduce the skill disparity, and improve patient outcomes. IntuScope is a patented Class I FDA Device featuring a reusable blade and reusable handle that utilizes a patient’s own anatomy and two actuating arms to open the airway. IntuScope makes intubation easier, faster, and safer in even the most difficult patients. While the device can be used for any intubation, the initial efforts will be focused on the pre-hospital market. ***** Would this bring value to your practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion. Sign up today! https://mergemedical.community.forum/ ***** DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

TECTON: Deep Dive Podcast

Ketones are the most pure form of energy that our body makes. Have these former Coca-Cola executives and the original founder created the ultimate multifunctional energy and health drink? “Deep Dive” or uncut version of our video podcast. Drs Jeff Brown and Jeff Cole interview Udaiyan Jatar (Co-Founder & CEO) and Joseph Motto (President & CFO) of Tecton. Tecton is a multifunctional health drink that is based on a breakthrough in exogenous ketone science. Its proprietary ketone molecule overcomes all the biggest barriers to mainstream adoption of exogenous ketones. It tastes good, it is safe even at very high doses (80-100 per day) for all age groups, and it is affordable. The product was designed to be completely safe and healthy with zero carbs, zero caffeine and it is clean label. This allows Tecton to be consumed for metabolic health at macronutrient levels, and therefore, serves as a foundation for weight management, brain health and physical performance. ***** Would this bring value to your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion. Sign up today! https://mergemedical.community.forum/ ***** DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

TECTON: 10 in 10 Podcast

Ketones are the most pure form of energy that our body makes. Have these former Coca-Cola executives and the original founder created the ultimate multifunctional energy and health drink? “10 in 10” or quick-hitting version of our video podcast. Drs Jeff Brown and Jeff Cole interview Udaiyan Jatar (Co-Founder & CEO) and Joseph Motto (President & CFO) of Tecton. Tecton is a multifunctional health drink that is based on a breakthrough in exogenous ketone science. Its proprietary ketone molecule overcomes all the biggest barriers to mainstream adoption of exogenous ketones. It tastes good, it is safe even at very high doses (80-100 per day) for all age groups, and it is affordable. The product was designed to be completely safe and healthy with zero carbs, zero caffeine and it is clean label. This allows Tecton to be consumed for metabolic health at macronutrient levels, and therefore, serves as a foundation for weight management, brain health and physical performance. ***** Would this bring value to your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion. Sign up today! https://mergemedical.community.forum/ ***** DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured. *****

DISCGENICS: Deep Dive Podcast

With a market cap of several hundred million, to call DiscGenics a “Startup” isn’t exactly true. This growth stage company has their eye on becoming a blockbuster (injectable) drug company. Can a new cell line (discogenic cells) revolutionize the way that spinal disc disease is treated and regenerate a failing disc? “Deep Dive” or uncut version of our video podcast. Drs Jeff Brown and Jeff Cole interview the founders of DiscGenics. DiscGenics is committed to revolutionizing the way millions of patients suffering from chronic back pain will be treated through a focus on developing regenerative therapies that alleviate pain and restore function in patients with degenerative diseases of the spine. They are engineering highly specialized therapeutic progenitor cells (Discogenic Cells) that uniquely address the complex environment of the degenerated disc. DiscGenics’ first product candidate, IDCT (rebonuputemcel), is a regenerative solution; an allogeneic, injectable (non-surgical) cell therapy that utilizes proprietary Discogenic Cells to treat mild to moderate adult lumbar disc degeneration. ***** Would this bring value to your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion. Sign up today! https://mergemedical.community.forum/ ***** DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

DISCGENICS: 10 in 10 Podcast

With a market cap of several hundred million, to call DiscGenics a “Startup” isn’t exactly true. This growth stage company has their eye on becoming a blockbuster (injectable) drug company. Can a new cell line (discogenic cells) revolutionize the way that spinal disc disease is treated and regenerate a failing disc? “10 in 10” or quick-hitting version of our video podcast. Drs Jeff Brown and Jeff Cole interview the founders of DiscGenics. DiscGenics is committed to revolutionizing the way millions of patients suffering from chronic back pain will be treated through a focus on developing regenerative therapies that alleviate pain and restore function in patients with degenerative diseases of the spine. They are engineering highly specialized therapeutic progenitor cells (Discogenic Cells) that uniquely address the complex environment of the degenerated disc. DiscGenics’ first product candidate, IDCT (rebonuputemcel), is a regenerative solution; an allogeneic, injectable (non-surgical) cell therapy that utilizes proprietary Discogenic Cells to treat mild to moderate adult lumbar disc degeneration. ***** Would this bring value to your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion. Sign up today! https://mergemedical.community.forum/ ***** DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.

4 di 4